MONICA SAMUEL AVILA GRINBERG

(Fonte: Lattes)
Índice h a partir de 2011
7
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: SILVIA MOREIRA AYUB FERREIRA × Categoria: original article × Indexador: MEDLINE × Assunto: Cardiac & Cardiovascular Systems ×

Resultados de Busca

Agora exibindo 1 - 4 de 4
  • article 4 Citação(ões) na Scopus
    Brazilian Society of Cardiology Guideline on Myocarditis-2022
    (2022) MONTERA, Marcelo Westerlund; MARCONDES-BRAGA, Fabiana G.; SIMOES, Marcus Vinicius; MOURA, Lidia Ana Zytynski; FERNANDES, Fabio; MANGINE, Sandrigo; OLIVEIRA JUNIOR, Amarino Carvalho de; SOUZA, Aurea Lucia Alves de Azevedo Grippa de; IANNI, Barbara Maria; ROCHITTE, Carlos Eduardo; MESQUITA, Claudio Tinoco; AZEVEDO FILHO, Clerio F. de; FREITAS, Dhayn Cassi de Almeida; MELO, Dirceu Thiago Pessoa de; BOCCHI, Edimar Alcides; HOROWITZ, Estela Suzana Kleiman; MESQUITA, Evandro Tinoco; OLIVEIRA, Guilherme H.; VILLACORTA, Humberto; ROSSI NETO, Joao Manoel; BARBOSA, Joao Marcos Bemfica; FIGUEIREDO NETO, Jose Albuquerque de; LUIZ, Louise Freire; HAJJAR, Ludhmila Abrahao; BECK-DA-SILVA, Luis; CAMPOS, Luiz Antonio de Almeida; DANZMANN, Luiz Claudio; BITTENCOURT, Marcelo Imbroise; GARCIA, Marcelo Iorio; AVILA, Monica Samuel; CLAUSELL, Nadine Oliveira; JR, Nilson Araujo de Oliveira; SILVESTRE, Odilson Marcos; SOUZA, Olga Ferreira de; MOURILHE-ROCHA, Ricardo; KALIL FILHO, Roberto; AL-KINDI, Sadeer G.; RASSI, Salvador; ALVES, Silvia Marinho Martins; FERREIRA, Silvia Moreira Ayub; RIZK, Stephanie Itala; MATTOS, Tiago Azevedo Costa; BARZILAI, Vitor; MARTINS, Wolney de Andrade; SCHULTHEISS, Heinz-Peter
  • article 26 Citação(ões) na Scopus
    Emerging Topics Update of the Brazilian Heart Failure Guideline-2021
    (2021) MARCONDES-BRAGA, Fabiana G.; MOURA, Lidia Ana Zytynski; ISSA, Victor Sarli; VIEIRA, Jefferson Luis; ROHDE, Luis Eduardo; SIMOES, Marcus Vinicius; FERNANDES-SILVA, Miguel Morita; RASSI, Salvador; ALVES, Silvia Marinho Martins; ALBUQUERQUE, Denilson Campos de; ALMEIDA, Dirceu Rodrigues de; BOCCHI, Edimar Alcides; RAMIRES, Felix Jose Alvarez; BACAL, Fernando; ROSSI NETO, Joao Manoel; DANZMANN, Luiz Claudio; MONTERA, Marcelo Westerlund; OLIVEIRA JUNIOR, Mucio Tavares de; CLAUSELL, Nadine; SILVESTRE, Odilson Marcos; BESTETTI, Reinaldo Bulgarelli; BERNADEZ-PEREIRA, Sabrina; JR, Aguinaldo F. Freitas; BIOLO, Andreia; BARRETTO, Antonio Carlos Pereira; JORGE, Antonio Jose Lagoeiro; BISELLI, Bruno; MONTENEGRO, Carlos Eduardo Lucena; SANTOS JUNIOR, Edval Gomes Dos; FIGUEIREDO, Estevao Lanna; FERNANDES, Fabio; SILVEIRA, Fabio Serra; ATIK, Fernando Antibas; BRITO, Flavio de Souza; SOUZA, Germano Emilio Conceicao; RIBEIRO, Gustavo Calado de Aguiar; VILLACORTA, Humberto; SOUZA NETO, Joao David de; GOLDRAICH, Livia Adams; BECK-DA-SILVA, Luis; CANESIN, Manoel Fernandes; BITTENCOURT, Marcelo Imbroinise; BONATTO, Marcely Gimenes; MOREIRA, Maria da Consolacao Vieira; AVILA, Monica Samuel; COELHO FILHO, Otavio Rizzi; SCHWARTZMANN, Pedro Vellosa; MOURILHE-ROCHA, Ricardo; MANGINI, Sandrigo; FERREIRA, Silvia Moreira Ayub; FIGUEIREDO NETO, Jose Albuquerque de; MESQUITA, Evandro Tinoco
  • article 7 Citação(ões) na Scopus
    The first cardiac transplant experience in a patient with mucopolysaccharidosis
    (2012) GRINBERG, Henrique; QUAIO, Caio Robledo D'Angioli Costa; AVILA, Monica Samuel; FERREIRA, Silvia Moreira Ayub; VIEIRA, Marcelo Luiz Campos; BENVENUTI, Luiz Alberto; KIM, Chong Ae; BOCCHI, Edimar Alcides
    Hunter syndrome (MPSII) is a rare X-linked lysosomal storage disorder that can affect multiple systems but primarily affects the heart. We report the case of a previously asymptomatic 23-year-old patient who had an attenuated form of MPSII and presented with refractory heart failure that required a heart transplant. The diagnosis was confirmed by detection of an increase in urinary excretion of glycosaminoglycans, a deficiency in enzymatic activity, and molecular analysis. A myocardial biopsy revealed hypertrophic cardiomyocytes, mild fibrosis, and lysosomal storage in interstitial cells. Molecular analysis identified a novel mutation in the iduronate-2-sulfatase gene. Although the clinical outcome was not favorable, we believe that this approach may be valid in end-stage heart failure.
  • article 348 Citação(ões) na Scopus
    Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity
    (2018) AVILA, Monica Samuel; AYUB-FERREIRA, Silvia Moreira; WANDERLEY JR., Mauro Rogerio de Barros; CRUZ, Fatima das Dores; BRANDAO, Sara Michelly Goncalves; RIGAUD, Vagner Oliveira Carvalho; HIGUCHI-DOS-SANTOS, Marilia Harumi; HAJJAR, Ludhmila Abrahao; KALIL FILHO, Roberto; HOFF, Paulo Marcelo; SAHADE, Marina; FERRARI, Marcela S. M.; COSTA, Romulo Leopoldo de Paula; MANO, Max Senna; CRUZ, Cecilia Beatriz Bittencourt Viana; ABDUCH, Maria Cristina; ALVES, Marco Stephan Lofrano; GUIMARAES, Guilherme Veiga; ISSA, Victor Sarli; BITTENCOURT, Marcio Sommer; BOCCHI, Edimar Alcides
    BACKGROUND Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Prevention with beta-blockers remains controversial. OBJECTIVES This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity. METHODS The authors randomized 200 patients with HER2-negative breast cancer tumor status and normal left ventricular ejection fraction (LVEF) referred for ANT (240 mg/m(2)) to receive carvedilol or placebo until chemotherapy completion. The primary endpoint was prevention of a >= 10% reduction in LVEF at 6 months. Secondary outcomes were effects of carvedilol on troponin I, B-type natriuretic peptide, and diastolic dysfunction. RESULTS Primary endpoint occurred in 14 patients (14.5%) in the carvedilol group and 13 patients (13.5%) in the placebo group (p = 1.0). No differences in changes of LVEF or B-type natriuretic peptide were noted between groups. A significant difference existed between groups in troponin I levels over time, with lower levels in the carvedilol group (p = 0.003). Additionally, a lower incidence of diastolic dysfunction was noted in the carvedilol group (p = 0.039). A nonsignificant trend toward a less-pronounced increase in LV end-diastolic diameter during the follow-up was noted in the carvedilol group (44.1 +/- 3.64 mm to 45.2 +/- 3.2 mm vs. 44.9 +/- 3.6 mm to 46.4 +/- 4.0 mm; p = 0.057). CONCLUSIONS In this largest clinical trial of beta-blockers for prevention of cardiotoxicity under contemporary ANT dosage, the authors noted a 13.5% to 14.5% incidence of cardiotoxicity. In this scenario, carvedilol had no impact on the incidence of early onset of LVEF reduction. However, the use of carvedilol resulted in a significant reduction in troponin levels and diastolic dysfunction.(Carvedilol Effect in Preventing Chemotherap-Induced Cardiotoxicity [CECCy] NCTO1724450)(C) 2018 by the American College of Cardiology Foundation.